The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024)
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
39174333
DOI
10.48095/ccko2024292
PII: 138290
Knihovny.cz E-resources
- Keywords
- ATM, BRCA1, BRCA2, CHEK2, PALB2, consensus, germline mutation carriers, guidelines for clinical practice,
- MeSH
- Ataxia Telangiectasia Mutated Proteins * genetics MeSH
- Checkpoint Kinase 2 * genetics MeSH
- Genetic Predisposition to Disease * MeSH
- Humans MeSH
- Prostatic Neoplasms genetics MeSH
- Breast Neoplasms genetics MeSH
- Pancreatic Neoplasms genetics MeSH
- Ovarian Neoplasms genetics MeSH
- BRCA1 Protein genetics MeSH
- BRCA2 Protein * genetics MeSH
- Fanconi Anemia Complementation Group N Protein * genetics MeSH
- Practice Guidelines as Topic MeSH
- Germ-Line Mutation * MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- ATM protein, human MeSH Browser
- Ataxia Telangiectasia Mutated Proteins * MeSH
- BRCA1 protein, human MeSH Browser
- BRCA2 protein, human MeSH Browser
- Checkpoint Kinase 2 * MeSH
- CHEK2 protein, human MeSH Browser
- PALB2 protein, human MeSH Browser
- BRCA1 Protein MeSH
- BRCA2 Protein * MeSH
- Fanconi Anemia Complementation Group N Protein * MeSH
The Guidelines for Clinical Practice for carriers of pathogenic variants in clinically relevant cancer predisposition genes define the steps of primary and secondary prevention that should be provided to these individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society (SLG ČLS JEP) in cooperation with the representatives of oncology and oncogynecology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.
References provided by Crossref.org
